Zhang et al., 2023 - Google Patents
Imaging cholinergic receptors in the brain by positron emission tomographyZhang et al., 2023
View HTML- Document ID
- 3599868307852774037
- Author
- Zhang J
- Fu H
- Lin R
- Zhou J
- Haider A
- Fang W
- Elghazawy N
- Rong J
- Chen J
- Li Y
- Ran C
- Collier T
- Chen Z
- Liang S
- Publication year
- Publication venue
- Journal of Medicinal Chemistry
External Links
Snippet
Cholinergic receptors represent a promising class of diagnostic and therapeutic targets due to their significant involvement in cognitive decline associated with neurological disorders and neurodegenerative diseases as well as cardiovascular impairment. Positron emission …
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0446—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
- A61K51/0493—Steroids, e.g. cholesterol, testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Li et al. | Synthesis and in vivo evaluation of a novel PET radiotracer for imaging of synaptic vesicle glycoprotein 2A (SV2A) in nonhuman primates | |
| Piel et al. | Positron emission tomography in CNS drug discovery and drug monitoring | |
| Ding et al. | Comparative evaluation of positron emission tomography radiotracers for imaging the norepinephrine transporter:(S, S) and (R, R) enantiomers of reboxetine analogs ([11C] methylreboxetine, 3‐Cl‐[11C] methylreboxetine and [18F] fluororeboxetine),(R)‐[11C] nisoxetine,[11C] oxaprotiline and [11C] lortalamine | |
| Goud et al. | Carbon-11: radiochemistry and target-based PET molecular imaging applications in oncology, cardiology, and neurology | |
| Fischer et al. | Molecular imaging of σ receptors: synthesis and evaluation of the potent σ1 selective radioligand [18F] fluspidine | |
| Fujinaga et al. | Synthesis and evaluation of novel radioligands for positron emission tomography imaging of metabotropic glutamate receptor subtype 1 (mGluR1) in rodent brain | |
| Zhang et al. | Imaging cholinergic receptors in the brain by positron emission tomography | |
| Hashimoto et al. | [11C] CHIBA-1001 as a novel PET ligand for α7 nicotinic receptors in the brain: a PET study in conscious monkeys | |
| Emond et al. | PE2I: a radiopharmaceutical for in vivo exploration of the dopamine transporter | |
| Waterhouse et al. | Halogenated 4-(phenoxymethyl) piperidines as potential radiolabeled probes for σ-1 receptors: in vivo evaluation of [123I]-1-(iodopropen-2-yl)-4-[(4-cyanophenoxy) methyl] piperidine | |
| Prante et al. | Radioligands for the dopamine receptor subtypes | |
| Brust et al. | Development of radioligands for the imaging of α7 nicotinic acetylcholine receptors with positron emission tomography | |
| Li et al. | Synthesis and evaluation of novel 18F-labeled spirocyclic piperidine derivatives as σ1 receptor ligands for positron emission tomography imaging | |
| Huang et al. | Development of effective PET and SPECT imaging agents for the serotonin transporter: has a twenty-year journey reached its destination? | |
| Takamura et al. | In vivo receptor visualization and evaluation of receptor occupancy with positron emission tomography | |
| Kim et al. | Screening of σ2 receptor ligands and in vivo evaluation of 11C-labeled 6, 7-Dimethoxy-2-[4-(4-methoxyphenyl) butan-2-yl]-1, 2, 3, 4-tetrahydroisoquinoline for potential use as a σ2 receptor brain PET tracer | |
| Ding et al. | New-generation radiotracers for nAChR and NET | |
| Cao et al. | Synthesis and Biological Evaluation of [18F] FECNT-d 4 as a Novel PET Agent for Dopamine Transporter Imaging | |
| Mori et al. | Development of 2-(2-(3-(4-([18F] Fluoromethoxy-d 2) phenyl)-7-methyl-4-oxo-3, 4-dihydroquinazolin-2-yl) ethyl)-4-isopropoxyisoindoline-1, 3-dione for Positron-Emission-Tomography Imaging of Phosphodiesterase 10A in the Brain | |
| Wang et al. | 2-(2′-((Dimethylamino) methyl)-4′-(3-[18F] fluoropropoxy)-phenylthio) benzenamine for positron emission tomography imaging of serotonin transporters | |
| Parhi et al. | 2-(2′-((Dimethylamino) methyl)-4′-(fluoroalkoxy)-phenylthio) benzenamine derivatives as serotonin transporter imaging agents | |
| Stehouwer et al. | Synthesis, fluorine-18 radiolabeling, and biological evaluation of N-((E)-4-fluorobut-2-en-1-yl)-2β-carbomethoxy-3β-(4′-halophenyl) nortropanes: candidate radioligands for in vivo imaging of the brain dopamine transporter with positron emission tomography | |
| Chen et al. | Preclinical evaluation of novel positron emission tomography (PET) probes for imaging leucine-rich repeat kinase 2 (LRRK2) | |
| Pimlott | Radiotracer development in psychiatry | |
| Elsinga | Nuclear medicine imaging tracers for neurology |